mirabegron + pioglitazone

Mirabegron + pioglitazone is a combination of two small molecule drugs, each with distinct mechanisms of action and approved indications. Mirabegron is a selective beta-3 adrenergic receptor agonist primarily used to treat overactive bladder and neurogenic detrusor overactivity by relaxing the detrusor muscle in the bladder, thereby increasing its storage capacity and reducing symptoms such as urgency, frequency, and incontinence[3][5][6][7]. Pioglitazone is a thiazolidinedione class drug that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity and glucose homeostasis; it is mainly indicated for type 2 diabetes mellitus[2]. The combination has been studied for potential metabolic benefits such as inducing beiging of white adipose tissue or increasing brown adipose tissue activity to improve glucose metabolism. However, clinical studies indicate that while both drugs individually can induce some beiging of adipose tissue and improve insulin sensitivity, their combination does not synergistically enhance these effects compared to monotherapy with either agent[1][4].

Brand names

Myrbetriq + Actos

Other names

None